Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells

Biochemical Pharmacology

Volumn 80, Issue 2, 2010, Pages 262-276

  Wu, Zchong Zcho ^a   Lu, Hsing Pang ^a   Chao, Chuck C K ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Cisplatin resistance; CITED2; NAPA; ShRNA

Indexed keywords

CISPLATIN; PACLITAXEL; SHORT HAIRPIN RNA; VINCRISTINE;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIZATION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR CELL; TUMOR RESISTANCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HELA CELLS; HUMANS; INVERTED REPEAT SEQUENCES; KIDNEY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 77952672714     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.029     Document Type: Article

References (31)

1. Chao C.C. Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review. J Formos Med Assoc 1996, 95:893-900.
2. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
3. Baird R.D., Kaye S.B. Drug resistance reversal-are we getting closer?. Eur J Cancer 2003, 39:2450-2461.
4. Dempke W., Voigt W., Grothey A., Hill B.T., Schmoll H.J. Cisplatin resistance and oncogenes-a review. Anticancer Drugs 2000, 11:225-236.
5. Niedner H., Christen R., Lin X., Kondo A., Howell S.B. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 2001, 60:1153-1160.
6. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
7. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31.
8. Wulfkuhle J., Espina V., Liotta L., Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 2004, 40:2623-2632.
9. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12:1294-1300.
10. Chao C.C., Lee Y.L., Cheng P.W., Lin-Chao S. Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum(II). Cancer Res 1991, 51:601-605.
11. Chang Y.S., Lin S.Y., Lee P.F., Durff T., Chung H.C., Tsai M.S. Establishment and characterization of a tumor cell line from human nasopharyngeal carcinoma tissue. Cancer Res 1989, 49:6752-6757.
12. Chao C.C. Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein. Eur J Pharmacol-Environ Toxicol Pharmacol 1996, 1:63-72.
13. Chao C.C., Ma C.M., Cheng P.W., Lin-Chao S. Increased mdr gene expression and decreased drug accumulation in a human colonic cancer cell line resistant to hydrophobic drugs. Biochem Biophys Res Commun 1990, 172:842-849.
14. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
15. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
16. Yang Y.H., Dudoit S., Luu P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30:e15.
17. Darzynkiewicz Z., Bruno S., Del B.G., Traganos F. The cell cycle effects of camptothecin. Ann NY Acad Sci 1996, 803:93-100.
18. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
19. Gonzalez V.M., Fuertes M.A., Alonso C., Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 2001, 59:657-663.
20. Clary D.O., Griff I.C., Rothman J.E. SNAPs, a family of NSF attachment proteins involved in intracellular membrane fusion in animals and yeast. Cell 1990, 61:709-721.
21. Martinez-Barbera J.P., Rodriguez T.A., Greene N.D.E., Weninger W.J., Simeone A., Copp A.J., et al. Folic acid prevents exencephaly in Cited2 deficient mice. Hum Mol Genet 2002, 11:283-293.
22. Yamasaki S., Yagishita N., Nishioka K., Nakajima T. The roles of synoviolin in crosstalk between endoplasmic reticulum stress-induced apoptosis and p53 pathway. Cell Cycle 2007, 11:1319-1323.
23. Yanagie H., Hisa T., Ogata A., Miyazaki A., Nonaka Y., Nishihira T., et al. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro. Biomed Pharmacother 2009, 63:553-560.
24. Vassilev A., Yamauchi J., Kotani T., Prives C., Avantaggiati M.L., Qin J., et al. The 400lkDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol Cell 1998, 2:869-875.
25. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001, 20:1331-1340.
26. Shi Y., Venkataraman S.L., Dodson G.E., Mabb A.M., LeBlanc S., Tibbetts R.S. Direct regulation of CREB transcriptional activity by ATM in response to genotoxic stress. Proc Natl Acad Sci USA 2004, 101:5898-5903.
27. Nakajima K., Hirose H., Taniguchi M., Kurashina H., Arasaki K., Nagahama M., et al. Involvement of BNIP1 in apoptosis and endoplasmic reticulum membrane fusion. EMBO J 2004, 23:3216-3226.
28. Hayakawa J., Mittal S., Wang Y., Korkmaz K.S., Adamson E., English C., et al. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 2004, 16:521-535.
29. Macleod K., Mullen P., Sewell J., Rabiasz G., Lawrie S., Miller E., et al. Altered erbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005, 65:6789-6800.
30. Kim M.-J., Jo D.-G., Hong G.-S., Kim B.J., Lai M., Cho D.-H., et al. Calpain-dependent cleavage of cain_cabin1 activates calcineurin to mediate calcium-triggered cell death. Proc Natl Acad Sci USA 2002, 99:9870-9875.
31. Riedel R.F., Porrello A., Pontzer E., Chenette E.J., Hsu D.S., Balakumaran B., et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008, 10:3141-3149.